undefined

Amin Agnes

Health insurance/business reporter who explains regulatory and market developments around compounded semaglutide (Wegovy) and the pricing pressures affecting Novo Nordisk.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app